| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology (Drs. Weinshenker and Wingerchuk), Department of Biochemistry and Molecular Biology (Drs. Liu and Sommer), Section of Biostatistics (Ms. Bissonet and Dr. Schaid), Department of Health Sciences Research, Mayo Clinic and Mayo Foundation, Rochester, MN; and the Department of Molecular Genetics (Drs. Liu and Sommer), City of Hope, Duarte, CA.
Address correspondence and reprint requests to Dr. Brian G. Weinshenker, Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.
The objective of this study was to determine whether sequence variation in the tumor necrosis factor alpha (TNF
) gene is associated with MS course and severity in Olmsted County, MN. The severity and temporal course of MS are heterogeneous. Genetic factors may play a role in determining the course of MS. TNF expression is temporally associated with exacerbations of MS and is increased in individuals with progressive disease. The entire TNF gene was amplified by polymerase chain reaction in 78 MS patients and in 39 patients with schizophrenia. Denaturation fingerprinting, a modification of direct sequencing that detects virtually all genetic polymorphisms, was performed for four regions spanning the functionally significant portions of the gene, including the promoter region. Polymorphisms were confirmed by complete sequencing. The severity and temporal course of MS were compared in those with wild-type versus variant alleles. Four sequence changes were detected, three of which occurred in MS patients. None occurred in a protein-encoding sequence. Neither of the two most common sequence variants were associated with disease severity or temporal course. Genetic variation of the TNF gene is not associated with variation in the course or long-term outcome of MS in this population-based sample.
Supported by grants from the Minnesota Northstar Chapter of the National Multiple Sclerosis Society and by Mayo Foundation.
Presented in part at the 48th annual meeting of the American Academy of Neurology; San Francisco, CA; March 27, 1996.
Received October 30, 1996. Accepted in final form February 9, 1997.
This article has been cited by other articles:
|
|
 |
|
  O. Gray, H Abdeen, G. McDonnell, C. Patterson, C. Graham, and S. Hawkins An investigation of susceptibility loci in benign, aggressive and primary progressive multiple sclerosis in Northern Irish population Multiple Sclerosis, March 1, 2009; 15(3): 299 - 303. [Abstract] [PDF]
|
|
|
|
 |
|
 L. F. Barcellos, S. Sawcer, P. P. Ramsay, S. E. Baranzini, G. Thomson, F. Briggs, B. C.A. Cree, A. B. Begovich, P. Villoslada, X. Montalban, et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis Hum. Mol. Genet., September 15, 2006; 15(18): 2813 - 2824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Burwick, P. P. Ramsay, J. L. Haines, S. L. Hauser, J. R. Oksenberg, M. A. Pericak-Vance, S. Schmidt, A. Compston, S. Sawcer, R. Cittadella, et al. APOE epsilon variation in multiple sclerosis susceptibility and disease severity: Some answers Neurology, May 9, 2006; 66(9): 1373 - 1383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H.S.R. Roxburgh, S. R. Seaman, T. Masterman, A. E. Hensiek, S. J. Sawcer, S. Vukusic, I. Achiti, C. Confavreux, M. Coustans, E. le Page, et al. Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity Neurology, April 12, 2005; 64(7): 1144 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. H. Kantarci, D. D. Hebrink, S. J. Achenbach, S. J. Pittock, A. Altintas, J. L. Schaefer-Klein, E. J. Atkinson, M. de Andrade, C. T. McMurray, M. Rodriguez, et al. Association of APOE polymorphisms with disease severity in MS is limited to women Neurology, March 9, 2004; 62(5): 811 - 814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kikuchi, T. Fukazawa, M. Niino, I. Yabe, R. Miyagishi, T. Hamada, S. A. Hashimoto, and K. Tashiro HLA-related subpopulations of MS in Japanese with and without oligoclonal IgG bands Neurology, February 25, 2003; 60(4): 647 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The Multiple Sclerosis Genetics Group, L. F. Barcellos, J. R. Oksenberg, A. J. Green, P. Bucher, J. B. Rimmler, S. Schmidt, M. E. Garcia, R. R Lincoln, M. A. Pericak-Vance, et al. Genetic basis for clinical expression in multiple sclerosis Brain, January 1, 2002; 125(1): 150 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Cepok, M. Jacobsen, S. Schock, B. Omer, S. Jaekel, I. Boddeker, W. H. Oertel, N. Sommer, and B. Hemmer Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis Brain, November 1, 2001; 124(11): 2169 - 2176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. G. Weinshenker, D. D. Hebrink, E. Atkinson, and O. H. Kantarci Association of a tumor necrosis factor {alpha} polymorphism with MS susceptibility Neurology, October 9, 2001; 57(7): 1341 - 1342. [Full Text] [PDF]
|
|
|
|
|
|
F. Fazekas, S. Strasser-Fuchs, H. Kollegger, T. Berger, W. Kristoferitsch, H. Schmidt, C. Enzinger, M. Schiefermeier, C. Schwarz, B. Kornek, et al. Apolipoprotein E {epsilon}4 is associated with rapid progression of multiple sclerosis Neurology, September 11, 2001; 57(5): 853 - 857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. G. Weinshenker and O. H. Kantarci Seeking genes for MS: Big risks for big gains Neurology, February 8, 2000; 54(3): 542 - 542. [Full Text] [PDF]
|
|
|
|
|
|
S J. Weatherby, C L. Mann, M B Davies, D Carthy, A A Fryer, M D Boggild, C Young, R C Strange, W Ollier, and C P Hawkins Polymorphisms of apolipoprotein E; outcome and susceptibility in multiple sclerosis Multiple Sclerosis, February 1, 2000; 6(1): 32 - 36. [Abstract] [PDF]
|
|
|
|
|
|
M. Fernandez-Arquero, R. Arroyo, A. Rubio, C. Martin, P. Vigil, L. Conejero, M. A. Figueredo, and E. G. de la Concha Primary association of a TNF gene polymorphism with susceptibility to multiple sclerosis Neurology, October 1, 1999; 53(6): 1361 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M A Armstrong, G V McDonnell, C A Graham, C W Kirk, A G Droogan, and S A Hawkins Relationship between tumour necrosis factor-alpha (TNF{alpha}) production and a specific multiple sclerosis (MS) associated TNF gene haplotype Multiple Sclerosis, June 1, 1999; 5(3): 165 - 170. [Abstract] [PDF]
|
|
|
|
|
|
D. Brassat, C. Azais-Vuillemin, J. Yaouanq, G. Semana, J. Reboul, I. Cournu, C. Mertens, G. Edan, O. Lyon-Caen, M. Clanet, et al. Familial factors influence disability in MS multiplex families Neurology, May 1, 1999; 52(8): 1632 - 1632. [Abstract] [Full Text]
|
|
|
|
|
|
B. G. Weinshenker, D. Hebrink, D. M. Wingerchuk, C. J. Klein, E. Atkinson, P. C. O'Brien, and C. T. McMurray Genetic variants in the tumor necrosis factor receptor 1 gene in patients with MS Neurology, April 1, 1999; 52(7): 1500 - 1500. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
